Serritella AV, Shevrin D, Heath EI, Wade JL, et al. Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clin Cancer Res 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
PMID: 35110415